Trial · NCT02654990
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) | Arm A - Panobinostat (20 mg, TIW) | 62.2 | 95% Confidence Interval 50.8 to 72.7 | percentage of participants | |
| Overall Response Rate (ORR) | Arm B - Panobinostat (20 mg, BIW) | 65.1 | 95% Confidence Interval 53.8 to 75.2 | percentage of participants | |
| Overall Response Rate (ORR) | Arm C - Panobinostat (10 mg, TIW) | 50.6 | 95% Confidence Interval 39.4 to 61.8 | percentage of participants | |
| ORR Throughout the Study | Arm A - Panobinostat (20 mg, TIW) | 62.2 | 95% Confidence Interval 50.8 to 72.7 | percentage of participants | |
| ORR Throughout the Study | Arm B - Panobinostat (20 mg, BIW) | 67.5 | 95% Confidence Interval 56.3 to 77.4 | percentage of participants | |
| ORR Throughout the Study | Arm C - Panobinostat (10 mg, TIW) | 53.0 | 95% Confidence Interval 41.7 to 64.1 | percentage of participants | |
| iCR Rate | Arm A - Panobinostat (20 mg, TIW) | 3.7 | percentage of participants | ||
| iCR Rate | Arm B - Panobinostat (20 mg, BIW) | 1.2 | percentage of participants | ||
| iCR Rate | Arm C - Panobinostat (10 mg, TIW) | 1.2 | percentage of participants | ||
| sCR Rate | Arm A - Panobinostat (20 mg, TIW) | 1.2 | percentage of participants | ||
| sCR Rate | Arm B - Panobinostat (20 mg, BIW) | 1.2 | percentage of participants | ||
| sCR Rate | Arm C - Panobinostat (10 mg, TIW) | 3.6 | percentage of participants | ||
| CR Rate | Arm A - Panobinostat (20 mg, TIW) | 8.5 | percentage of participants | ||
| CR Rate | Arm B - Panobinostat (20 mg, BIW) | 8.4 | percentage of participants | ||
| CR Rate | Arm C - Panobinostat (10 mg, TIW) | 2.4 | percentage of participants | ||
| VGPR Rate | Arm A - Panobinostat (20 mg, TIW) | 19.5 | percentage of participants | ||
| VGPR Rate | Arm B - Panobinostat (20 mg, BIW) | 25.3 | percentage of participants | ||
| VGPR Rate | Arm C - Panobinostat (10 mg, TIW) | 20.5 | percentage of participants | ||
| Progression-free Survival (PFS) | Arm A - Panobinostat (20 mg, TIW) | 15 | 95% Confidence Interval 7.4 to 24.7 | months | |
| Progression-free Survival (PFS) | Arm B - Panobinostat (20 mg, BIW) | 13 | 95% Confidence Interval 7.0 to 13.8 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02654990/results